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THE NEXT STEP IN GENE PATENTS:
ASSOCIATION FOR MOLECULAR PATHOLOGY
v. MYRIAD GENETICS
I. INTRODUCTION
Patent law in the United States, in regards to biology in
particular, has produced bewildering decisions.' In one such
recent decision, the Supreme Court declared DNA to be un-
patentable in Ass'n for Molecular Pathology v. Myriad Genetics,
Inc..2 However, in its decision, the court ignored the widespread
implications to biological research. The Supreme Court decided,
clearly and without ambiguity, that genes and the information
contained in genes are not eligible for patents under Section 101 of
the Patent Act.' The Court further stated that complementary
DNA (cDNA) is something new that is created by a lab technician
and therefore is patentable.4 While this unambiguous language
seemed like it would be enough to prevent any confusion, the
Supreme Court chose to ignore the incredible diversity and
complexity that comes with anything biological and its effect on
any scientific research. Homologous genes are an example of this
ignored diversity. These genes are type of diversity that should
give the Supreme Court pause before making such a far-reaching
decision without at least discussing the effects on scientific
research in its opinion. Otherwise, the Court reaches decisions
that push against the very reason patent law exists: to promote
future invention. The Court should more thoroughly rely on the
briefs filed before the decision in order to draw the necessary
1. See Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013) (denying farmers
the ability to reproduce seeds that they had already purchased).
2. Ass'n for Molecular Pathology v. Myriad Genetic, Inc., 133 S. Ct. 2107
(2013).
3. Id. at 2120.
4. Myriad, 133 S. Ct. at 2119. cDNA is the information portion of DNA,
made from mRNA. See infra Part II/D.
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conclusions that scientists spend their wholes lives mastering.'
The Supreme Court needs to be specific in both its policy rationale
and reasoning behind its scientific decisions; otherwise their
opinions will impede scientific research or be ignored.
This note begins by working through the history and the
arguments for patenting DNA, comparing those arguments to those
against patenting DNA, and highlighting the differences between
the two.' With those arguments in mind, this note then analyzes
the facts and reasoning of the Court in Myriad and analyzes why it
should have included more depth to its discussion.' This note
concludes by arguing that the choice made in the Myriad decision
to ignore policy implications will cause needless litigation and
limit biological research.' In order to avoid this result in the
future, the Court would be better served pre-empting some of the
negative effects of a decision by addressing known problems in
their opinion instead of choosing to ignore them.
II. BACKGROUND
In order to understand the Court's holding in Myriad and the
analysis of that decision, a background in both genetics and
biology patents is necessary. In section A, this note will expand
upon the concept that a patent is the sole right to exclude others
from creating, using or selling an invention.' Parts B and C will
show that, despite common misconception, the patent process can
be applied to biological devices, including genes."o Part D will
then compare different arguments for and against patenting genes;
for example, they are designed to incentivize innovation, but they
5. See Declaration of Fiona E. Murray, Ph.D., Ass'n for Molecular
Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013) (No. 09-4515), 2010
WL 2643076.
6. See infra Part II.
7. See infra Part II/E and III.
8. See infra Part IV.
9. 35 U.S.C. § 271(a) (2010); see infra Part II/A.
10. See Amgen, Inc. v. Chugai Pharmaceutical, 927 F.2d 1200 (Fed. Cir.
1991); see May Mowzoon, Access Versus Incentive: Balancing Policies in
Genetic Patents, 35 ARIZ ST. L. J. 1077, 1085 (2003); see infra Part 11/1-C.
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may limit life-saving research." Part E will provide enough basic
information on genetics to enable the reader to understand the
Supreme Court's holding in Myriad. Finally, Part F will describe
the facts surrounding the Myriad decision.
A. What is a Patent?
Patents provide the sole right to exclude others from creating,
using, or selling an invention. 2 The basis for United States patent
law is Article I, Section 8, Clause 8 of the U.S. Constitution, which
is designed "to promote the Progress of Science and useful Arts,
by securing for limited Times to Authors and Inventors the
exclusive Right to their respective Writings and Discoveries.""
As the basis for patents, Congress has defined materials that are
patentable under Section 101 of the Patent Act, which states:
"Whoever invents or discovers any new and useful ... composition
of matter, or any new and useful improvement thereof, may obtain
a patent therefor, subject to the conditions and requirements of this
title." 4
A patent is the grant of the exclusive right over an invention and
prevents others from the right to make, use, or commercialize that
invention." Importantly, patents are not self-enforcing, which
means that a patent-holder must initiate any legal proceedings
against the patent-infringer. However, infringement suits bring
the risk that the court will narrowly interpret a patent, which may
11. Amanda S. Pitcher, Contrary to First Impression, Genes are Patentable:
Should There be Limitations?, 6 J. HEALTH CARE L. & POL'Y 284, 296 (2003)
(citing James Bradshaw, Gene Patent Policy: Does Issuing Gene Patents
Accord With the Purposes of the U.S. Patent System, 37 WILLAMETTE L. REV.
637, 645 (2001)).
12. 35 U.S.C. § 271(a).
13. Sherry M. Knowles & Stephanie D. Adams, Who Owns My DNA?: The
National and International Property Laws on Human Embryonic Tissue and
Cloning, 32 CUMB. L. REV. 475, 480 (2002).
14. 35 U.S.C. §101 (2013).
15. Amanda S. Pitcher, Contrary to First Impression, Genes are Patentable:
Should There be Limitations?, 6 J. HEALTH CARE L. & POL'Y 284-85 (2003).
16. May Mowzoon, Access Versus Incentive: Balancing Policies in Genetic
Patents, 35 ARIZ ST. L. J. 1077, 1085 (2003).
2014] 405
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limit or even repeal the rights of the patent-holder altogether; thus,
infringement suits are filed with care." Myriad is a perfect
example of how a company's attempt to enforce a patent brought
down a limitation of that patent by the U.S. government." Myriad
Genetics, Inc. attempted to enforce one of their gene patents and
the alleged infringers objected to their patent, resulting in the
Supreme Court's limitation to their patent rights. 9
In order to obtain a patent, an invention must be new, non-
obvious, useful, and fall under one of the categories specified.2 0
The invention must have a level of improvement over any previous
related invention that someone of ordinary skill would not have
been able to create.2' Additionally, the invention must be novel.22
Natural products, abstract ideas, laws of nature, scientific
principles, and physical phenomena are not patentable subjects.23
For example, wind is not patentable but the hang-glider that
utilizes the wind is. Applications for patents must divulge how to
create the invention in such a way that an ordinary person in the
same field can create or utilize the invention.24
B. Patenting Biology
For many years, biological products or products of nature were
not patentable.2 5 The 1948 case of Funk Brothers Seed Co. v. Kalo
Inoculant Co. was the first case before the Supreme Court
concerning patenting natural products.26 The respondent had
combined several different species of bacteria that spread over the
17. Id.
18. See generally Myriad, 133 S. Ct. 2107.
19. Id. at 2114.
20. Mowzoon, supra note 16, at 1083 ("Patentable subject matter consists of
'new and useful process, machine, manufacture, or composition of matter or any
new and useful improvement thereof.').
21. Id.
22. Id.
23. Id.
24. Id.
25. Knowles & Adams, supra note 13, at 480.
26. See generally Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S.
127 (1948); Pitcher, supra note 15, at 284.
406
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seeds of plants and helped the adult plants take in nitrogen.2 7 The
court held that simply combining several existing species of
bacteria into one product was not patentable because all of the
components of the invention were known and naturally
occurring. 28 The court reasoned that a product needs to be more
than just new and useful to qualify as an invention; it must also
meet the other elements of discovery.2 9
The courts next tackled gene patentability in 1958 in Merck &
Co. v. Olin Mathieson Chemical Corp.3 0 In Merck & Co., the court
held that a purified vitamin was patentable."1 It found that the
product of nature was transformed into a new and useful
composition and was therefore patentable.32 Similarly, the court
found that the purified natural product known as adrenalin was
patentable." The court said the product certainly exists in nature,
but the invention (its concentrated form) was not anticipated and is
entitled to patent protection.34 The court held that both of these
inventions were patentable.35 The court reasoned that even though
an element of the invention was a product of nature, the
purification of the vitamin or adrenalin gave a new use for the
product in a new form that was not possible in its original form.36
Therefore, if a purified vitamin is patentable, than other purified
natural materials were patentable."
It was not until 1980 that the Supreme Court first endorsed a
patent on a living organism in Diamond v. Chakrabarty." In
Diamond v. Chakrabarty, the respondent, Chakrabarty, created a
27. Funk, 333 U.S. at 129.
28. Id. at 294.
29. Id. at 132.
30. See generally Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d
156 (1958).
31. Id. at 164.
32. Id.; Pitcher, supra note 15, at 294.
33. Merck & Co., 253 F.2d at 162, citing Parke-Davis & Co. v. H. K.
Mulford & Co., 196 F.2d 496 (10th Cir. 1912).
34. Merck & Co., 253 F.2d at 162.
35. Id
36. Id at 164.
37. Id.
38. Knowles & Adams, supra note 13, at 480.
2014] 407
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bacterium that would be useful in cleaning up oil spills. 39 There
were no naturally occurring bacteria that had the same qualities as
the bacterium created.40  The Court held that a human-made
bacterium was patentable.4' Most importantly, Chakrabarty is
known for asserting that "anything under the sun that is made by
man" is patentable through the United States Patent and
Trademark Office (USPTO).4 2
In 1987, the next significant step in the evolution of the
patentability of biological technologies occurred in Ex parte
Allen.43 In Allen, the respondent challenged the rejection of a
patent over the method of inducing polyploidy (a cell nucleus
containing multiple DNA chromosomes of the same type) in
oysters." While the claim was ultimately rejected on obviousness
grounds, the Board of Patent Appeals and Interference stated it
was clear from Chakrabarty that multicellular organisms were
patentable. 45  The Board found that not only was the genes
patentable, but the whole organism could be patentable.4 6
Currently, the only relevant question concerning biological
patentability is whether the subject matter is made by man.47 This
decision was made official when the USPTO announced that
"nonnaturally occurring nonhuman multicellular living organisms,
including animals to be patentable subject matter within the scope
of 35 U.S.C. § 101."48
In 1993, the United States Court of Appeals for the Federal
Circuit in In re Bell, found that genes were not unpatentable
simply because the amino acid sequence of the corresponding
39. Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980).
40. Id. at 305.
41. Id. at 318.
42. Knowles & Adams, supra note 13, at 480.
43. See generally Ex parte Allen, 2 U.S.P.Q.2d 1425 (Bd. Pat. App. &
Interf. Apr. 3, 1987).
44. Knowles & Adams, supra note 13, at 481.
45. Exparte Allen, 2 U.S.P.Q.2d at 2.
46. Id.
47. Id.
48. Knowles & Adams, supra note 13, at 481 (quoting 1077 Official Gazette
U.S. Pat. & Trademark Off. 24 (April 21, 1987)).
408
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protein were known.4 9 In Bell, the court found that the protein
sequence, the list of amino acids that make up the protein, does not
necessarily make the DNA sequence (a gene) obvious."o In
addition, the court found that the genes were patentable as they
were chemical compounds and chemical compounds have always
been able to be patented." Therefore, the court reasoned that
protein sequences were patentable and a patent for a protein does
not preclude the corresponding DNA from being patented.52 In
order to patent a gene, the DNA sequence must be disclosed; a
reference in the patent application to the gene with respect to the
known amino acid sequence is not enough.53 Since 1993, the
USPTO have issued several thousand gene patents.54 As of 2003,
there were more than three million gene-related patents filed."
C. Why Patent Genes?
Economically, gene patents are enormously valuable to a
pharmaceutical company." Traditionally, drug companies spend
hundreds of millions of dollars on trial and error research, research
which involves the invention of a drug and efficacy testing on
patients." The costs associated with the development of a drug
include all of the unsuccessful trials, the subjects, and the research
that belongs to the process." However, with the completion of the
Human Genome Project and the relative ease of DNA sequencing,
the new method of inventing drugs is by designing them to fit a
gene." Scientists can identify specific molecules or strands of
49. In re Bell, 991, F.2d 781, 783 (Fed. Cir. 1993).
50. Id. at 784.
51. Amgen, Inc. v. Chugai Pharmaceutical, 927 F.2d 1200, 1206 (Fed. Cir.
1991).
52. Bell, 991 F.2d at 784.
53. Pitcher, supra note 15, at 295-96 (citing Fiers v. Revel, 984 F.2d 1164
(Fed. Cir. 1993)).
54. Pitcher, supra note 15, at 284.
55. Mowzoon, supra note 16, at 1086.
56. Id.
57. Id.
58. Id.
59. Pitcher, supra note 15, at 284; Mowzoon, supra note 16, at 1086.
2014] 409
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DNA that lead to a higher likelihood of disease and create drugs
that target those specific molecules or sequences.o
A gene patent allows companies to spend money on research
and profit from their investments by licensing the use of their
patent.6 1 The major obstacle in patenting genes is that the
knowledge of the gene sequence or location is not enough.6 2 The
entire human genome is sequenced, but in order to apply for a
patent, the company that is attempting to patent a gene must have a
known use for it."
D. Supporting and Opposing Arguments For Gene Patents
Patents are designed to incentivize discovery.' Incentives are
derived from the ability to license out a patent, or to give
somebody the ability to work with patented material in exchange
for money.6 5 Without this licensing ability, many companies
would be unable to support themselves, a significant amount of
genetic research would never come to fruition, and a great number
of cures for diseases would never have been found.66
However, the patent system is not without its drawbacks. With
such a large number of gene patents coming through the USPTO,
the risk of double patenting is increasing." A double patent would
occur when the genes that are being patented overlap, or if the
USPTO simply approves two similar patents for a gene.6 8 Double
patents would lead to double the licensing fees, which would
prevent a large number of companies from research."
Additionally, the patent system promotes competition between
60. Mowzoon, supra note 16, at 1086.
61. See generally id
62. Id. at 1087.
63. Id. at 1088.
64. Pitcher, supra note 15, at 296 (citing James Bradshaw, Gene Patent
Policy: Does Issuing Gene Patents Accord With the Purposes of the US. Patent
System, 37 WILLAMETTE L. REv. 637, 645 (2001)).
65. Pitcher, supra note 15, at 296.
66. Id. at 296-97.
67. Mowzoon, supra note 16, at 1086; Pitcher, supra note 15, at 297.
68. Pitcher, supra note 15, at 297.
69. Id.
410
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companies. 0 Competition, while a benefit to the free market, leads
to companies researching the same genes, inhibiting research into
new and possibly beneficial genes." This research, if completed
successfully by one company, provides that company with the
licensing incentives that come along with the patent, which would
then ultimately lead to a monopoly, as one company would receive
all of the income with which to continue researching.72
In addition to the economic risk of gene patents, there are
several other arguments against gene patents. One such argument
is that a patent on the purified form of the gene is barred from
being patented because it is a product of nature." Purified genes
exist as they do in nature, just in a more concentrated form without
the other DNA.74 Therefore, the patented purified gene can be said
to be the natural product in a different form, similar to the
argument for the patent on adrenaline." Another argument is that
gene patents are essentially the patents of an individual's
chromosome." The patenting of an individual's DNA could be
considered immoral and a violation of an individual's rights to
their own body.n
A final drawback to the patent system, and the drawback that
most concerns this article, are the health benefits that are limited
by gene patents. Patients with treatable genetic conditions or an
increased risk of a certain disease due to their genetic makeup are
less likely to be able to afford or find laboratories that will conduct
the necessary tests to treat their condition." Additionally, those
7 0. Id.
71. Id. at 298.
72. Id.
73. David B. Resnik, DNA Patents and Human Dignity, 29 J. L. MED &
ETHIcs 152, 154 (2001).
74. Id.
75. Amgen, Inc., 927 F.2d at 1206; Merck & Co., 253 F.2d at 162, citing
Parke-Davis & Co. v. H. K. Mulford & Co., 196 F.2d 496 (10th Cir. 1912).
76. Pitcher, supra note 15, at 298 (citing John Murray, Owning Genes:
Disputes Involving DNA Sequence Patents, 75 CHI.-KENT L. REv. 231, 231
(1999)).
77. Vincent Y. Ling, Patently Ours? Constitutional Challenges to DNA
Patents, 14 U. PA.J. CONST. L. 813, 844 (2012).
78. Pitcher, supra note 15 at 298.
2014] 411
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that do find laboratories that have paid the licensing fee for their
specific test will be forced to pay an increased and sometimes
unaffordable cost for the test. 9 To enforce a patent, a company
may shut down or prevent a life-saving test being performed by a
third party, preventing that potential patient from receiving
treatment."0
E. Genetics
Genes, the product at issue in Myriad, are the basis for all
hereditary traits in living organisms." The human genome has
about 22,000 genes divided up among 23 chromosomes, made up
of deoxyribonucleic acid (DNA), forming a double helix.82 Each
side of the helix is complementary towards each other, joined as
nucleotides: adenine, thymine, cytosine, and guanine." When
strung together into certain sequences, these nucleotides code for
amino acids, which combine to form proteins.84 However, some
sequences do not code for any amino acids. This is called junk
DNA or introns, while the coding DNA is called exons."
The creation of proteins involves breaking apart the DNA
double helix, reading one strand of that broken-down helix to
create an identical mirror strand of ribonucleic acid (RNA), and
then putting the helix back together.86 The RNA that is formed is
then spliced, cutting out all of the non-coding introns and leaving
the coding section intact." The exon-only strand, known as
79. Ling, supra note 76, at 821. Miami Children's Hospital, holder of a
gene patent, charged a $12.50 royalty fee per test for Canavan syndrome. Id.
80. See generally Myriad, 133 S. Ct. at 2114.
81. Mowzoon, supra note 16, at 1078.
82. BRUCE ALBERTS ET AL. MOLECULAR BIOLOGY OF THE CELL 344
(Marjorie Anderson and Sherry Granum, 5th ed. 2008); Chromosomes, National
Human Genome Research Institute, (November 27, 2013, 10:00AM),
http://www.genome.gov/26524120 ; A Brief Guide to Genomics, National
Human Genome Research Institute, (November 27, 2013, 10:00AM),
http://www.genome.gov/18016863.
83. Id. at 3.
84. Id. at 6.
85. Id. 206.
86. Id. at 332-34.
87. Id. at 347.
412
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messenger RNA (mRNA), is then read by parts of the cell to create
the protein."
Scientists can manipulate this process, extracting DNA from
cells using well-known methods." They can even isolate specific
segments of DNA in order to manipulate it."o One of these
processes is the creation of complementary DNA.9 1 To create
cDNA, the scientists take the mRNA, the exon-only strand, and
create the reverse image in DNA form, essentially creating an
intron free version of DNA.92 In Myriad, the Supreme Court
declared that cDNA is not a naturally occurring substance."
There are a large number of changes or mutations that occur in
DNA over time, such as mutations caused by radiation or reactive
oxygen species (chemically reactive molecules containing
oxygen).9 4 Mutations in DNA cause the proteins that they code for
to malfunction and malfunctioning proteins are a factor in
developing cancer.95 These mutations need to be fixed, and
organisms have developed several ways of repairing the mutations,
from homologous recombination to non-homologous end joining.96
In humans, one of the ways to fix the mutations is through the
breast cancer susceptibility gene 1 (BRCAl)." This gene along
with BRCA2, found while screening for mutations that lead to
breast cancer, are involved in homologous recombination." These
two genes code for proteins that correct mutations.9 9 The average
American woman has a 12-13% risk of developing breast cancer
88. ALBERTS, supra note 82, at 399-400.
89. Myriad, 133 S. Ct. at 2112.
90. Id.
91. Id.
92. ALBERTS, supra note 82, at 542.
93. Myriad, 133 S. Ct. at 2119.
94. Oliver Trapp, Katharina Seeliger & Holger Puchta, Homologs of Breast
Cancer Genes in Plants, 2 FRONTIERS IN PLANT SCIENCE 19, 1-2011.
95. See generally Trapp, supra note 94, at 1.
96. Trapp, supra note 94, at 1; ALBERTS, supra note 82, at 302-03 (Non-
homologous end-joining is when the broken ends of DNA are brought back
together and rejoined. Homologous recombination repairs DNA break using a
sister chromatid as a template.).
97. Id. at 1-2.
98. Id.
99. Id.
2014] 413
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but mutations in these genes increase the risk of breast cancer by
80% and of ovarian cancer by up to 50%.100 BRCAl and 2's role
in the human body is vital and complex and they function with a
diverse number of partners with many distinct functions.'o'
F. Myriad Genetics, Inc.
The Respondent in this case, Myriad Genetics, Inc., discovered
the precise location of two incredibly important genes (BRCAl
and BRCA2) that helped predict breast and ovarian cancer
susceptibility.102  Empowered with their new- find, Myriad
developed numerous tests that are useful for detecting mutations in
BRCAl and 2 and therefore detecting a patient's risk of breast or
ovarian cancer.' 3 In order to protect its discovery, Myriad applied
for, and was granted, numerous patents that gave it the exclusive
right to isolate an individual's BRCAl and 2 genes through any
isolation technique, essentially patenting the DNA.'" The patents
also gave Myriad the right to synthetically create BRCA cDNA.'
However, isolation of genes, especially ones as important as
BRCAl and BRCA2, is the only way to conduct genetic testing on
them.'06 Upon learning of the test to help determine their patients'
risk of breast cancer, doctors all over the nation began utilizing
that knowledge.' The Petitioners in this case, the doctors from
around the nation, soon lost that ability after Myriad sent cease and
desist letters.'0 o Myriad also filed patent infringement suits,
resulting in settlements, in an effort to create a monopoly on
BRCAl and 2 testing.'09 Petitioners filed a lawsuit, seeking to
invalidate Myriad's patents under the Patent Act."o
100. Myriad, 133 S. Ct. at 2113.
101. See id.
102. Id.
103. Id. at 2113-14.
104. Id. at 2114.
105. Id.
106. Myriad, 133 S. Ct. at 2114.
107. See generally id.
108. Id. at 2114.
109. Id.
110. Id.
414
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The Supreme Court held that DNA is not patent eligible, but
cDNA is patentable, nullifying Myriad's DNA patents but
upholding the cDNA patents."' The court reasoned that Myriad
did not create nor alter any of the BRCA1 and 2 genes.112 They
simply discovered the location of them."' Myriad was attempting
to patent the actual DNA sequence, not the isolation process.114
Unfortunately for Myriad, discovery does not by itself satisfy
patentability, no matter how extensive the effort required."'
The Supreme Court further reasoned that the process used to
create complementary DNA makes it clear that cDNA is not a
naturally occurring product."6 A lab technician is required to use
his skills to create something brand new, using the naturally
occurring RNA."' The Supreme Court held that cDNA, except
when short enough to be indistinguishable from naturally
occurring DNA, is patent eligible under the Patent Act." 8
III. ANALYSIS: HOMOLOGY: AN EXAMPLE OF THE MYRIAD
DECISION'S LACK OF POLICY DISCUSSION THAT
CREATES CONFUSION
Myriad marked one of the most significant Court opinions
concerning biotechnology of 2013."9 The Court's new bright line
rule concerning the inability to patent DNA and the patentability
of cDNAl2 o is clear and easy to follow on its surface. However,
the Court chose not to address the impact their decision would
have on scientific research and in failing to do so has opened the
door to untold litigation.12' The existence and use of homologous
111. Id. at 2111.
112. Myriad, 133 S. Ct. at 2116.
113. Id.
114. Id. at 2113, 2119.
115. Id. at 2117-18.
116. Id. at 2119.
117. Id.
118. Myriad, 133 S. Ct. at 2119.
119. See generally Myriad, 133 S. Ct. 2107.
120. Id. at 2120 (holding that genes and the information contained within
them are not patent eligible, but cDNA is patentable).
121. See generally Myriad, 133 S. Ct. 2107.
2014] 415
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genes is an example of an area of litigation the Court has created
with its new rule. Homologous genes are identical genes in
different organisms and scientists rely on them when studying and
researching DNA.122 These scientists often use cDNA libraries,
created from the homologous genes, in their research.123 Creating
cDNA from genes homologous to a patented gene violates the new
rule created by the Supreme Court. Since homologous cDNA
creation is a violation, the Myriad decision will severely limit the
ability of scientists to study and research human diseases.124 The
Supreme Court either did not consider the broad reaching
implications on scientific research or it considered those
implications and decided not to address the limitations they were
imposing on future invention and research.
A. Homology and How it Relates to Myriad
A concept that the Supreme Court overlooked and that will lead
to a significant amount of litigation relates to homology. To
designate a pair of genes as homologous is to designate them as
sharing a common ancestor.'2 5 Two subcategories of homology to
be aware of are orthologs, genes that originate from the last
common ancestor of the two species, and paralogs, genes that are
related due to gene duplication.'2 6 Homology is important because
homologous genes are virtually identical to each other but they
exist in different species.'2 7 Further, homologous genes typically
perform equivalent functions in their respective organisms.'28
Their functional equivalency leads to homologous genes being
referred to as the same genes in different species.'2 9 Homology has
enormous implications and uses in the study of evolutionary and
122. See Trapp, supra note 94, at 3.
123. See generally ALBERTS, supra note 82, at 544.
124. See generally Myriad, 133 S. Ct. 2107 (2013).
125. Eugene v. Koonin, Orthologs, Paralogs, and Evolutionary Genomics,
39 Annual Review of Genetics 309, 311 (2005).
126. Id. at 311.
127. Id.
128. Id. at 313.
129. Id. at 316.
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functional genomics.3 o Unfortunately for the Supreme Court, it
was also immensely impacted by their decision in Myriad.
Mutation suppression genes are vital to fighting cancer in almost
all organisms."' Homologs for the human version of these
mutation suppressors have been found in many different
organisms, including yeast, fruit flies, and mice. 3 2 Therefore, it is
very likely that homologs for BRCAl and 2 exist as well.'33
In the present case, Myriad discovered the location of the breast
cancer susceptibility gene in human beings.'34 Mutations in
BRCAl or 2 are vital to DNA mutation repair, so if they are
mutated themselves, it is incredibly damaging to the cell."' Since
BRCAl and 2 are vital to repairing mutations, it should be no
surprise that homologs of these genes have been found in other
animals.'36 However, surprisingly, homologs of BRCAl have been
found in organisms as different from us as plants, specifically in
Arabidopsis."'
The discovery of BRCAl genes in plants does not affect
Myriad's patent claims. The Supreme Court ruled that genes and
the information they contain are not patent eligible."' The court
did not specify which organism's natural genes, nor did it limit the
holding in any way."' Genes are not patentable.'4 0 However, what
scientists can do with those genes is patentable; the applications of
BRCA knowledge are infinite.14
130. Id. at 333.
131. See Trapp, supra note 94, at 1.
132. Frank B. Dean, et al., cDNA Cloning and Gene Mapping of Human
Homologs for Schizosaccharomyces pombe radl 7, rad1, and husI and Cloning
of Homologs from Mouse, Caenorhabditis elegans, and Drosophila
melanogaster, 54 (3) Genomics 424, 425 (1998).
133. See generally Trapp, supra note 94.
134. Myriad, 133 S. Ct. at 2112.
135. Trapp, supra note 94, at 1.
136. Id.
137. Id. at 3.
138. Myriad, 133 S. Ct. at 2120.
139. Id. at 2119-20.
140. Id.
141. Id (stating that "Myriad was in an excellent position to claim
application of that knowledge").
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B. Analyzing the Homology Problem
The problem lies in the Supreme Court's declaration that cDNA
is patentable.142 Complementary DNA is vital to the study and
research of DNA and can be made from many different
organisms.'43 If the cDNA is patentable, then the study of any
homologous genes from any other organisms becomes impossible
without first getting the licensing rights from the patent holder. As
with all patents, it does not matter how you get to the end product,
as long as the end product has been patented already.'" The
patentability of cDNA has the potential to cripple life-saving DNA
research because it does not matter from what organism you create
the cDNA, it is a violation of the patent if the end result is the
patented product.
To be clear, the court in Myriad held that genes and the
information that they code for is not patentable, no matter how
extensive the effort is that discovers it.'45 The Supreme Court also
held that the techniques used to isolate the DNA and create the
cDNA are not patentable.'4 6 However, the cDNA that is made
based on the discovered, isolated, and non-patentable DNA is
patentable.'4 7
With respect to the information encoded in DNA, cDNA and the
DNA it is based on code for the exact same information.'48 By
definition, cDNA is formed from mRNA, which contains only the
coding sequence of DNA.'49 The Supreme Court's holding that the
information DNA encodes for is not patentable but that cDNA is
patentable, implies that the physical sequence itself is patented, not
what it can do, where it is derived from, nor the information it
holds.'" This note ignores, as the Supreme Court chose to, the
142. Myriad, 133 S. Ct. at 2119.
143. See generally ROBERT F. WEAVER, MOLECULAR BIOLOGY 64 (Patrick
E. Reidy, 4thed. 2008).
144. See generally 35 U.S.C. §101.
145. Myriad, 133 S. Ct. at 2118.
146. Id. at 2119-20.
147. Id. at 2119.
148. See WEAVER, supra note 143, at 64.
149. Myriad, 133 S. Ct. at 2119.
150. See id. at 2119-20.
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argument that cDNA is intron-free DNA, similar to DNA found in
prokaryotic organisms, and therefore found in nature."' It focuses
solely on the conflict created with homology.
Isolated DNA is not patentable. 5 2  In Myriad, the DNA is
isolated from one specific species: humans.'" Thus, the cDNA
created from the strand of human DNA that was located and
isolated by lab technicians is a new product. 5 4  The physical
sequence of the cDNA, the string of nucleotides, is patentable, not
the information contained within.'
When applied to homologous genes, this reasoning seems to
apply easily enough. Homologous genes are naturally occurring
and therefore are not patent eligible.' cDNA is patent eligible
because it is not naturally occurring.' The cDNA that is formed
from a homologous gene violates the patent for the cDNA from the
human gene, as the homologous genes are essentially identical to
each other.
The court's decision makes it clear that the cDNA made from
the DNA of another organism is patented with the human cDNA
patent.' Despite the time and effort that is still required to find,
isolate, and make the new cDNA, the result is an identical product
to the already patented cDNA, so all that work created a violation
of the original patent. For example, if scientists and lab
technicians were to locate and isolate the BRCAl gene in
Arabidopsis and then create cDNA from that plant's gene, it would
violate Myriad's patent on the BRCAl cDNA gene.'59
151. See Vic Norris & Robert Root-Bernstein, The Eukaryotic Cell
Originated in the Integration and Redistribution of Hyperstructures from
Communities ofProkaryotic Cells Based on Molecular Complementarity, 10 (6)
Int J. Mol Sci. 2611, 2611-32 (2009).
152. See Myriad, 133 S. Ct. at 2116.
153. Id. at2llO-11.
154. Id. at 2119.
155. Id. at 2120 (stating that "[w]e merely hold that genes and the
information they encode are not patent eligible").
156. Mowzoon, supra note 16, at 1083.
157. Myriad, 133 S. Ct. at 2119.
158. Id.
159. Trapp, supra note 94, at 2. The location and isolation of the BRCA
gene in Arabidopsis is possible. Id.
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To really see this problem, first look to the court's reasoning on
why DNA is not patentable. 0 DNA is a natural product that does
not change, no matter the time or effort spent finding and isolating
it.16 ' cDNA is un-natural and therefore patentable because that
sequence of DNA is not found naturally in nature. 6 2 However, the
court in Myriad never examines or discusses the source of cDNA,
nor how cDNA is used.163 Its definitive statement is that the
physical sequence of cDNA is patentable.'" Obviously, as cDNA
and DNA code for the same information, the information
contained in cDNA is not patentable. Therefore, the sequence of
nucleotides from the cDNA formed from the homologous gene is
an exact match and the cDNA derived from Arabidopsis would be
a violation of that patent.
The holding in Myriad is problematic as cDNA from multiple
species is useful for scientific study and research.' 5 In order to
study how mutations in genes affect organisms, scientists will
often intentionally mutate a gene or breed for mutations, leading to
deformities at birth as well as potential death.'66 Studying specific
genes in human beings is often problematic due to the ethical and
moral problems of intentionally killing or deforming human
beings. In order to work around the limitations on human
experimentation, scientists often use models (organisms that have
homologous genes) in order to safely and effectively perform
genetic studies, especially when mutations in the target genes
cause death."' A mutation in the BRCAl gene during
development in the womb is often lethal, making study of
mutations in humans for that gene both difficult and unethical.' 8
Scientists can use alternative models, such as Arabidopsis, in order
to conduct their research.'69 This plant is good alternative to
160. See generally Myriad, 133 S. Ct. 2107 (2013).
161. Id. at 2120.
162. Id. at 2119.
163. See generally Myriad, 133 S. Ct. 2107.
164. Id. at 2120.
165. Id.
166. Trapp, supra note 94, at 2.
167. See generally Trapp, supra note 94.
168. Id. at 2.
169. Id. at 13.
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human subjects because mutation in the BRCA gene does not
cause embryonic death and therefore the effect of the mutation can
be studied during the organism's life.'
In order to study the gene in models, cDNA is usually created."'
cDNA is more useful to researchers than mRNA, the natural and
therefore unpatentable product of the cell, because the DNA form
is significantly more stable and the techniques for amplifying and
therefore studying them are easier to use.'72 When studying genes,
scientists will often create cDNA libraries, a collection of cDNA
clones derived from the active mRNA in a cell."' In this way,
scientists can often see which genes are active in the cell at a given
time and what the cell is doing.'74 In addition, cDNA is created in
order to study the proteins encoded by their parent DNA. "'
However, because cDNA is too small and delicate for individual
manipulation, they can be used as a template in rapid cloning
techniques to generate large amounts of DNA sufficient for
study.'76
It is during the study and research of DNA that the Supreme
Court ruling in Myriad poses the problem. Patents and patent
protections, when applied liberally, hinder innovation and impede
the flow of information.'77  When patents are too restricted,
advancement stalls because incentives to innovate are too
miniscule to put forth the effort required.7 7 Here, the Supreme
Court applied its patent protections too liberally. Scientists will be
unable to create the cDNA libraries necessary to study genes, such
as BRCAl, without paying fees to the patent holder, Myriad
Genetics, Inc. The most confusing aspect of the Court's refusal to
address the policy implications is that it knew the patents were
170. Id.
171. ALBERTS, supra note 82, at 543-44.
172. See Id.
173. Id. at 542.
174. Id.
175. Id at 544.
176. See Id. at 540, 546.
177. Brief for the United States as Amicus Curiae in Support of Neither
Party at 33, Ass'nfor Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct.
2107, (2013) (No. 12-398) 2013 WL 390999.
178. Id. at 53.
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negatively affecting research.'7 9 The Court should have explained
why they chose to ignore this incredibly crucial effect of their
decision on potentially life-saving research.
If the holding in Myriad is not reconsidered or at least explained,
scientists will be unable to create the cDNA necessary to study
genes in their models, severely limiting any advancement. The
Supreme Court, in making this broad decision, should have
explained why they chose to ignore the policy. Justice Scalia in
his concurrence, declared his knowledge of molecular biology too
limited to effectively decide, which could explain the lack of
policy implications expressed in the decision: it was just too
complex to be understood by the Court. "' Despite a known
deficiency of scientific knowledge, Justice Scalia still concurred
with the overall holding of the majority."' Without expressing the
key implications to their decision, the Court is opening itself up to
being ignored. For example, Myriad Genetics, Inc. has taken the
Supreme Court's holding, disregarded it, and has recently sued for
patent infringement.182 If this type of case were to reach the
Supreme Court again, which seems likely due to the complications
imposed by the policy, the Supreme Court would need to address
the issues in order to draft a lasting opinion.
179. Declaration of Fiona E. Murray, supra note 5.
[T]he Myriad patents at issue in the instant lawsuit are likely to have negatively
impacted the accumulation of public knowledge of the BRCAl and BRCA2
genes by between 5 and 10%. The negative impact of the patents at issue is
exacerbated by the fact that Myriad Genetics is an assignee from the private
sector, the patents in question are exceedingly broad, and the genes at issue are
cancer genes.
Id.
180. Myriad, 133 S. Ct. at 2120 (J. Scalia, concurring).
18 1. Id.
182. Mike Masnick, Myriad Mocks Supreme Court's Ruling On Gene
Patents; Sues New Competitors Doing Breast Cancer Tests, TECHDIRT
(November 27, 2013, 8:00AM), available at
http://www.techdirt.com/articles/20130713/01171423788/ myriad-mocks-
supreme-courts-ruling-gene-patents-sues-new-competitors-doing-breast-cancer-
tests.shtml.
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IV. CONCLUSION
The Supreme Court developed a bright line rule when they
wrote the Myriad decision: genes and the information contained
within them are not patent eligible but cDNA is patent eligible.1 3
However clear and easy to follow this rule appears to be, it ignores
policy implications caused by basic genetic concepts, such as
homology. The creation of cDNA from homologous genes is a
violation of the new Supreme Court rule. If this holding is
enforced, scientists will be severely limited in their ability to study
life threatening mutations or conduct medical research that could
save lives. The Supreme Court, in making decisions that
negatively affect an area of life-saving science, needs to be clear in
why they are ruling a specific way. Without explaining or at least
touching upon these impacts on science, scientists are forced into
boundless litigation in order to continue their work or define the
limit set by the decision. Alternatively, the decision may simply
be ignored, much like it already has been.184 To avoid either
consequence, the Supreme Court should anticipate future litigation
by choosing to address some of the negative consequences of their
decision, such as limitations on research, instead of ignoring these
obvious concerns.
Ryan Leal*
183. See generally Myriad, 133 S. Ct. 2107.
184. Masnick, supra note 182 (Myriad has continued to sue using one of its
other patents on the BRCA 1 and 2 genes, claiming the Supreme Court only
invalidated 5 of 520 patent claims from its 24 patents instead of invalidating
DNA patents in general. For example, it has sued Ambry Genetics, claiming the
isolation of the BRCA1 and 2 genes by any isolation method from a woman to
test for cancer is a violation of their patent. While not technically a DNA
patent, it is essentially a DNA patent, which violates the Supreme Court
holding.)
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